ARTIST-2

NCT01761461 📎

Regimen

Experimental
adjuvant SOX x6 mo, or SOX + 45 Gy chemoradiotherapy (SOXRT)
Control
adjuvant S-1 monotherapy x1 year

Population

D2-resected stage II/III node-positive gastric cancer

Key finding

3y DFS 64.8% (S-1) vs 74.3% (SOX, HR 0.692, P=0.042) vs 72.8% (SOXRT, HR 0.724, P=0.074); SOX vs SOXRT no difference (HR 0.971)

Source: PMID 33278599

Timeline

    Guideline citations

    • NCCN GASTRIC (p.127)
    • CSCO GASTRIC 2025 (p.72)⚠️ OCR source